Thursday handed Wall Street a little of everything: a heavyweight slipping, a borrowing spree, and a trading pause nobody saw coming.

Economic data pulled in two directions while the major averages mostly shrugged and waited for someone to blink. Beneath that calm surface, the real action was somewhere far less polite, and the best part is still ahead of you.

One NASDAQ company is already delivering. 558% YoY revenue growth. Paid Air Force and Navy trials done. 26 acquisitions complete. Quantum defense initiative underway.

Stock at $199M while peers trade at $685M–$7B. Maxim has a $5 target.

Unlock the full story now

*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.

Alphabet had its worst session on record, shedding roughly $500 billion in market value as worries about search share, AI mode, and heavy cash burn piled up, dragging the tech-heavy Nasdaq with it. Microsoft sold $25 billion of bonds, a hefty raise that shows how pricey the AI race has become. Prediction market Polymarket paused trading after funds were reportedly drained.

On the economic front, GDP came in strong while inflation data ran hot, a pairing that keeps rate cut hopes on a short leash.

Traders now wonder whether the Fed can ease at all with prices running this warm. WTI crude hovered near $102 as traders bet on Iran de-escalation. Small caps caught a bid and bucked the tech-led slide as investors looked beyond the mega caps.

Merck plans to raise its long-term sales forecast for new medicines above $70 billion, citing clinical progress and recently acquired treatments as it prepares for Keytruda’s main patent expiration in 2028. 

GoodRx launched a nationwide employer program for weight-loss medicines, allowing businesses to choose covered treatments and contribution levels while providing employees access to GLP-1 drugs without changing existing health plans.

Franklin Templeton launched two ETFs that combine U.S. stocks with Bitcoin, using automatic dividend reinvestment into cryptocurrency to gradually increase Bitcoin exposure in portfolios initially allocated primarily to equities.

Robinhood became the first integration partner for Uniswap’s new fee-conversion system, using automated conversions into USDC and USDG to consolidate cryptocurrency trading fees collected across supported blockchains.

One analyst believes Elon Musk is preparing to launch the biggest project of his career — and says the key date is December 8.

He claims the clues are already buried in government filings, along with one investment move he believes should be made before December 9.

His full case is laid out in a free masterclass.

See What Elon Filed Before December 8

Perrigo agreed to sell its infant formula business for up to $175 million, with payments tied partly to future performance as buyer MeridianMade offers $40 million at closing and up to $135 million linked to milestones through 2030.

ADT agreed to be acquired by Thrive Holdings for $7.6 billion, accepting an all-cash deal worth $10 per share that would take the home-security company private, with completion expected in the first quarter of 2027 and subsequent delisting from the NYSE.

Glaukos [GKOS] $242.48 (+33.65%)

Glaukos posted a quarter that made analysts do the math twice: $211 million in sales, up 58%, with iDose TR and Epioxa doing the heavy lifting.

Management then raised its full-year outlook by about $90 million at the midpoint and floated a $1 billion 2027. Add a debt-free balance sheet, and the stock sailed through its eye exam.

ADT [ADT] $9.87 (+33.20%)

ADT spent years selling peace of mind, and now Thrive Holdings, led by Josh Kushner, is buying the company for $10 a share in cash, roughly $7.6 billion in equity value.

Apollo-managed funds back it, with no financing condition. Shares closed at $9.87, a hair under the offer, which is the market politely saying it expects the paperwork to clear.

Porch Group [PRCH] $20.89 (+28.16%)

Porch Group’s home insurance flywheel kept spinning: revenue of $143.9 million cruised past the $133.4 million consensus, and adjusted EPS of $0.10 dwarfed a one-cent estimate

Guidance went up for the third straight quarter, and the stock gapped higher at the open. Turns out investors still love a company that quietly keeps raising its own bar.

Iovance Biotherapeutics [IOVA] $9.56 (-35.45%)

Iovance served up lung cancer data on lifileucel in 69 patients, and about 25% responded, which matched earlier reports. Investors wanted an encore and got a rerun.

The therapy struggled in patients with the KRAS mutation, though smokers without KRAS or HER2 mutations fared far better. A new study arm arrives in November, with an FDA filing targeted for 2027.

ServiceNow [NOW] $109.67 (-26.64%)

ServiceNow cleared the bar on third-quarter results, then handed investors a fourth-quarter outlook that did not, and AI disruption fears did the rest.

Few software names get punished this hard for a beat, but when the worry is that smarter tools could reshape how software is bought, the market sells first and reads footnotes later.

Alnylam Pharmaceuticals [ALNY] $174.00 (-25.13%)

Alnylam grew revenue 52% to $1.29 billion, with Amvuttra U.S. sales up 69% to $909 million, and still got sold.

The culprit: new patient starts are converting more slowly than management wants, and TTR sales look headed for the low end of guidance. Operating margin slid from 38% to 29%. Great growth, apparently, is no longer enough.

The national debt just crossed $40 trillion — about $117,000 for every man, woman and child in America.

Here's the per-person math.

You'll never get an invoice. Washington collects a little at a time, from the buying power of everything you've saved.

Here's how to keep your share off the table.

Foreign buyers of U.S. debt are stepping back and buying something else instead.

Claim your complimentary guide here.

*This is an advertisement. If you no longer wish to receive promotional emails, please unsubscribe here or write to: 203 Heritage Grove Road, Leander, TX 78641

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.